Low HDL ‘stable marker’ of high triglycerides, diabetes doubles heart failure risk — top stories in endocrinology
Click Here to Manage Email Alerts
Researchers found that HDL cholesterol levels can be used to monitor high triglyceride levels and remnant cholesterol, similar to how high HbA1c can indicate long-term glucose levels. This was one of the top stories in endocrinology last week.
Another top story was about a study that showed heart failure occurs more often in patients with type 2 diabetes.
Low HDL cholesterol ‘stable marker’ of high triglycerides
Low HDL cholesterol levels can be used to monitor long-term, average high triglyceride levels and remnant cholesterol in much the same way a high HbA1c is an indicator of long-term, average high glucose levels, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.
Diabetes doubles heart failure risk
Heart failure occurs more frequently among adults with type 2 diabetes vs. those without the disease and can be considered an independent risk factor for the condition, according to findings from a population study published in Mayo Clinic Proceedings. Read more.
Weight gain raises diabetes risk for adults with prediabetes despite normal BMI
Among Japanese adults with prediabetes who had normal weight, overweight or obesity, those who progressed to diabetes during an 8-year period had greater increases in BMI and waist circumference than those who maintained their prediabetes status or converted to normal glycemic levels, according to findings published in Clinical Nutrition. Read more.
Trajectory of secondhand smoke exposure influences type 2 diabetes risk
Korean adults who were exposed to a stable, consistent level of secondhand smoke throughout the life course were less likely to develop type 2 diabetes when compared with adults previously exposed to high levels of secondhand smoke followed by reduced levels, according to findings published in BMJ Open Diabetes Research & Care. Read more.
Liraglutide shows antiresorptive effect on bone in type 2 diabetes
A cohort of adults with type 2 diabetes assigned the GLP-1 receptor agonist liraglutide for 26 weeks experienced a preservation in hip and spine bone mineral density and no changes in bone resorption markers despite weight loss, suggesting the drug may have an antiresorptive effect, according to findings published in Bone. Read more.